Boothwyn Pharmacy LLC, Kennett Square, PA

Is Boothwyn Pharmacy LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Boothwyn Pharmacy LLC hold a Pennsylvania pharmacy license?

State board of pharmacy records for Pennsylvania are not checked: the Department of State’s license lookup (PALS) did not respond on November 6, 2026, and when tried again on November 7, 2026 it answered with a script-driven search application, which this index does not use; its monthly discipline reports are listed only through a script-driven search page. The California State Board of Pharmacy also lists nonresident license NRP 1963 for Boothwyn Pharmacy, Kennett Square, PA, status Active and license NSC 101082 for Boothwyn Pharmacy Llc, Kennett Square, PA, status Delinquent, as of Nov 6, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 7011 for Boothwyn Pharmacy, Kennett Square, PA, status Active - Restricted, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054020439 for BOOTHWYN PHARMACY LLC, KENNETT SQUARE, PA, status ACTIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002758 for BOOTHWYN PHARMACY, KENNETT SQUARE, PA, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0000767 for Boothwyn Pharmacy, LLC, KENNETT SQUARE, PA, status Active, as of Nov 10, 2026.

Has Boothwyn Pharmacy LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jan 16, 2026) for Boothwyn Pharmacy LLC. FDA’s posted warning letters that name a GLP-1 drug include one to Boothwyn Pharmacy LLC, dated Jan 16, 2026. State board of pharmacy records for Pennsylvania are not checked: the Department of State’s license lookup (PALS) did not respond on November 6, 2026, and when tried again on November 7, 2026 it answered with a script-driven search application, which this index does not use; its monthly discipline reports are listed only through a script-driven search page. The Colorado State Board of Pharmacy’s license dataset also lists “CLS Stipulation” dated Oct 9, 2026, case 2025-8788 on nonresident license OSP 7011. The Maryland Board of Pharmacy’s posted orders against permit holders also lists “CONSENT ORDER” dated Jul 7, 2026 on nonresident permit P05923.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Boothwyn Pharmacy LLC
Location
Kennett Square, PA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
3
Warning letters on FDA’s actions page
1
Latest action on that page
Jan 16, 2026
FDA Data Dashboard inspections
4 inspections: 4 OAI; 4 published Form 483s
Form 483 text on this page
3 Form 483s, 19 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Boothwyn Pharmacy LLC, a 503A facility, with 5 dated actions.

Document
Jan 16, 2026Warning letterWarning Letter Issued 01/16/2026fda.gov
Jun 9, 2025Form 483483 Issued 06/09/2025fda.gov
May 13, 2024Regulatory meetingRegulatory Meeting Held 05/13/2024Not linked by FDA
Sep 12, 2023Amended Form 483Amended 483 Issued 9/12/2023FDA copy (archived)
Sep 8, 2021Form 483483 Issued 09/08/2021FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Boothwyn Pharmacy LLC, Kennett Square, PA (FEI number 1000076625), matched to this page by exact name, city and state. It lists 4 inspections: 4 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 9, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)10000766251269896
Oct 22, 2024Official Action Indicated (OAI)Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary)10000766251249428
Aug 29, 2023Official Action Indicated (OAI)Drug Quality Assurance (Drugs)10000766251217606
Jun 16, 2017Official Action Indicated (OAI)Drug Quality Assurance (Drugs)10000766251015508

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 19 numbered observations in all, across 3 inspections ending Sep 8, 2021 to Oct 22, 2024. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Sep 23, 2024 to Oct 22, 2024: 5 observations

Firm on the cover
Boothwyn Pharmacy LLC, 221 Gale Ln, Kennett Square, PA 19348
FEI number
1000076625
Establishment type on the cover
Producer of Sterile and Non-Sterile Drug Products
FDA district office on the cover
US Customhouse Rrn 900 200 Chestnut St Philadelphia, PA 19106
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

Specifically,

A. Your firm distributed seven (7) batches of your drug products using Certificates of Analysis (COAs) containing passing bacterial endotoxin testing (BET) results when in fact the COAs pulled from your contracted testing laboratory's database indicate that the true results of the BET were Out of Specification (OOS):

Date Made

Product Name

Batch Number

Failing Results

Specification w/Failing Results

False Passing Results

Specification w/ Passing Results

03132023@ <Redacted B4> 530.40 EU/ml <Redacted B4> 27.23 EU/ml

<Redacted B4>

HA/ CHONDROITIN/ ACETYl-D-k;LUCOSAMINE (100Ml ) »MG/50MG/150MG/Ml INJ $OlUTION

HA/ CHONDROITIN/ ACETYl-D-k;LUCOSAMINE (100Ml ) »MG/50MG/150MG/Ml INJ 5OlUTION

07142023@ <Redacted B4> 706.59 EU/ml

<100.00 EU/ml

HA/ CHONDROITIN/ ACETYl-D-k;LUCOSAMINE (100Ml ) 5MG/50MG/150MG/Ml INJ 5OLUTION

10052023@ <Redacted B4> 398.37 EU/ml

177.09 EU/ml

5OLUTION

(b) (4) (b) (4)

~CETYL-D-GLUCOSAMINE * (100ML) ~00 MG/Ml INJ SOLUTION

10062023@ <Redacted B4> 559.99 EU/ml

126.01 EU/ml ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.

Specifically,

A. Review of your firm's air visualization "smoke" study videos shows insufficiencies for example:

I. Your media fills and smoke studies are not representative of your production operations. For example, during the execution of your media fill studies titled, Media Fill Testing {Smoke Study} High Risk lnj Solution 08162024@ <Redacted B4> and 08162024@ <Redacted B4> and Smoke Studies Smoke Study 08.16.24 PS-169 FDA (Hazardous Sterile Filling Room) and Smoke Study 08.16.24 PS-172 FDA {Non-Haz Sterile Filling Room), you utilized the services of a second operator to assist your filling technician. The secondary operator in both videos were observed entering into the ISO 5 environment while your filling technician maintained their hands inside the same ISO 5 environment. Per SOP, SOP ID: CP.CTECH.0040.000 ASEPTIC TECHNIQUE, section 6.4.14, only one (1) trained pharmacist or pharmacy technician may be in the ISO Class 5 environment at a time. ...

Read the full 483 (PDF on fda.gov)

Observation 3

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been aheady distributed.

Specifically, your firm did not investigate the multiple Out of Specification (OOS) failures for bacterial endotoxin t esting (BET).

A. Your firm provided OOS lnvestigational Reports for eighteen (18) of thirty-one (31) batches conducted by your firm that were generated specifically for the purposes of this FDA Inspection and were not taken at the time of occurrence. Your firm management stated that none of the actions identified in the documents were taken as corrections nor was there an investigation into the root cause(s) for the failing endotoxin results. For example, the investigations contain a call log indicating that patients and/ or their prescriber were contacted regarding the BET results and to inquire if patients suffered any adverse effects due to the contaminated product. None of the patients or their prescribers were contacted. ...

Read the full 483 (PDF on fda.gov)

Observation 4

The quality control unit lacks the responsibility and authority to approve all components and drng products.

Specifically, your quality unit did not conduct any final review or approval of the COAs received from your contracted testing laboratory. There were a total number of thirty-one (31) bat ches that received an OOS result of which seven (7) COAs were altered to show passing results for BET. Review of your bat ch records does not show any indication of a receipt and review of the COAs received from your contracted testing laboratory. Further, the Logged Formula Worksheet, Final Observation and Status, allows for the entry of the sterility and endotoxin results received from your contracted testing laboratory, a pharmacist verification of the results and an overall batch disposition, however it is not utilized. There is no indication of who has final approval of your executed batch records and their testing results.

Observation 5

Repo1is ofanalysis from component suppliers are accepted in lieu oftesting each component for conformity with all appropriate written specifications, without establishing the reliability ofthe supplier's analyses through appropriate validation ofthe supplier's test results at appropriate intervals.

Specifically, you do not verify the conformance of a product to the manufacturer COA for any of the active pharmaceutical ingredients received into your facility or to ensure that components utilized by your firm are pharmaceutical grade. For example, the COAs issued by one of your suppliers for N-Acetyl-D -Glucosamine USP, lots <Redacted B4>, and <Redacted B4> states "FOR NUTRACEUTICAL USE ONLY". You distributed the following drug products containing glucosamine that were out of specification for endotoxin by this supplier:

distributed the following drug products containing glucosamine that w ere out of specification for endotoxin by this supplier:

Date made

Name

Lot Number

API Lot number

HA/ CHONDROITIN/ ACETYL-D-GLUCOSAMINE (l00ML) 5MG/ 50MG/ 150MG/ ML INJ SOLUTION

07142023@ <Redacted B4> <Redacted B4>

HA/ CHONDROITIN/ ACETYL-D-GLUCOSAMINE (l00ML) 5MG/ 50MG/ 150MG/ ML INJ SOLUTION ...

Read the full 483 (PDF on fda.gov)

Inspection Aug 9, 2023 to Aug 29, 2023: 5 observations

Firm on the cover
Boothwyn Pharmacy LLC, 221 Gale Ln, Kennett Square, PA 19348
FEI number
1000076625
Establishment type on the cover
Producer of sterile and non-sterile drug products
FDA district office on the cover
US Customhouse Rrn 900 200 Chestnut St Philadelphia, PA 19106
Matched to this page by
FEI number on the cover; linked from actions page
FDA document
Read the full 483 (Internet Archive copy FDA links)

Observation 1

Smoke studies were inadequately performed under dynamic conditions.

Specifically, unidirectional airflow was not verified under dynamic operational conditions representative of your aseptic processing practices. Air visualization studies ("smoke studies") performed in your ISO 5 classified b

safety cabinet <Reda ct ed B4> and in your ISO 5 classified laminar airflow wo rkbench <R edacted B4> in June 2023 do not demonstrate the movement of first air around equipment, supplies, or operator manipulations as observed during sterile product operations. Your technician was observed blocking first air making it difficult to observe its movement within the ISO5 area and did not complete <Redacted B4> activit ies wh ich is p art of product ion as obser ved dur ing the production of Alprostadil/Papaverine HCl/Phentolamine Mesylate (Tri-Mix) lot 080920203@ <Redacted B4>

iological

Observation 2

The facility design was observed to allow the influx of lesser quality air into a classified area containing higher quality air.

Specifically, your non-hazardous drug preparation room, <Redacted B4> and your hazardous drug preparation room, <Redacted B4> share a vent which increases the possibility of cross contamination. For example:

A. The vent between <Redacted B4> and <Redacted B4> increases the possibility of air flow from a lesser quality (ISO 8) area <Redacted B4> into a higher quality (ISO 7) area <Redacted B4> to be exhausted through the <Redacted B4> hoods where production prep activities such as weighing of hazardous drug <Redacted B4> and blending operations take place.

AMENDMENT 1

B. The vent between <Redacted B4> and <Redacted B4> does not provide adequate segregation to prevent cross contamination between the hazardous drug and non-hazardous drug rooms. There is no continuous differential pressure monitoring in your hazardous drug or non-hazardous drug cleanroom suites or real time alarm to alert staff when there is a change in differential pressures.

Observation 3

Use of non-sterile cleaning wipes in the ISO 5 area.

Specifically your technicians were observed using I wipes, during cleaning operations <Redacted B4> aseptic production wliich inclucle cleaning of the hard to clean surfaces of the hoods), that were taken from a bulk packet of 300 wipes which is cut open on its side and located outside of the ISO 5 classified area.

-~ ~1

For example,

LJ

A. On August 9, 2023, technician was observed using the <Redacte d B4> w ipes during the aseptic production of Alprostadil/Papaverine HCl/Phentolamine Mesylate (Tri- Mix) lot 080920203@<Redacted B4>

B. On August 18, 2023, technician <Redacted B 4> was observed using the <Re d acted B4> wipes during aseptic production of Altrenogest (20mL) lot 08182023@<Redacted B4> f

Observation 4

AMENDMENT 1

Specifically,

A On August 18, 2023, your technician <Redacted B4> did not clean the <Redacted B4> located <Redacted B4> the ISO 8 classified preparation room <Redacted B4> and the ISO 7 classified buffer room <Redacted B4>, with a sporicidal agent, or any cleaning agent, during direct observation of the <Redacted B4> cleaning of the sterile suite containing the LAFW.

B On August 18, 2023, your technician <Redacted B4> was observed to be inconsistently cleaning the walls of the ISO 7 and ISO 8 classified rooms as parts of the walls showed no evidence of wetness during the <Redacted B4> cleaning of rooms <Redacted B4>.

Observation 5

Hazardous drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.

Specifically,

A. On August 9,2023 your technician <Redacted B4> did not spray their gloves with a deactivatin g agent or ch ange th eir gl oves after measuring proges teron e <R edact ed B4> and th en pro ceeded to tou ch ot her ite ms, such as <Re dacted B4> (lot < Redacte d B4 > an d <Re dacted B4> (Lot <R edac ted B4>), d uri ng the produc tion of P rogest erone 200mg/ml Cream (lot 08092023@ <Redacted B4>

B. On August 16, 2023, your technician <Redacted B4> when donning their gowning before preparation operations of Medroxyprogesterone Acetate 200mg/mL lot 08162023@ <Redacted B4> allowed the ties of their sterile smock to touch the ground in during gowning procedures. The ties were then wrapped around their waist, tying them at the front of their waist.

AMENDM ENT 1

Inspection Aug 17, 2021 to Sep 8, 2021: 9 observations

Firm on the cover
Boothwyn Pharmacy LLC, 221 Gale Ln, Kennett Square, PA 19348
FEI number
1000076625
Establishment type on the cover
Producer of sterile and non-sterile drug products
FDA district office on the cover
US Customhouse Rm 900 200 Chestnut St Philadelphia, PA 19106
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Personnel conducted aseptic manipulations and placed equipment/supplies in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.

Specifically,

On August 19, 2021, during sterile production of "TRICHLORMETHAZIDE-DEXAMETHASONE ACETATE 10 MG/0.5 MG/ML INJ" (lot 08192021@11) and "GLYCOPYRROLATE 0.2 MG/ML INJ" (lot 08192021@12), in the biological safety cabinet (BSC), your pharmacy technician ' ' manipulated sterile connections between the respective <Redacted B4> housing units and the <Redacted B4> sterile vials such that the filter housing blocked the exposed vial openings from first pass air. Moreover, the pharmacy technician's left hand blocked first pass air to the vials immediately to the left of those being filled for approximately half of thellvials of each lot.

Observation 2

You produced hazardous drugs without providing adequate containment, segregation, cleaning of work smfaces, cleaning of utensils and cleaning ofpersonnel to prevent cross-contamination.

Specifically,

A. On August 19, 2021, your phannacy technician <Redacted B4> did not clean the interior ceiling ' grate" of the BSC before and after producing "TRICHLORMETHAZIDE-DEXAMETHASONE ACETATE 10 MG/0.5 MG/ML INJ" (lot 08192021 @11) and "GLYCOPYRROLATE 0.2 MG/ML INJ" (lot 08192021 12), purported to be sterile. She stated she does not clean the ceiling 'grate" during routine <Redacted B4>, or <Redacted B4> cleaning, nor between products. Hazardous products are routinely produced in the BSC such as "PROGESTERONE 150 MG/ML INJ" (lot 08172021 @4) produced on August 17, 2021.

B. On August 20, 2021 , your pharmacy technician <Redacted B4> did not clean the interior back wall "grate" of the laminar airflow workstation (LAFW) before and after producing "AMMONTIJM CHLORIDE 2% INJ' (lot 08202021 purported to be sterile. He stated he does not clean the back wall "grate" of the LAFW during routine <Redacted B4> cleaning, nor between products.

C . ...

Read the full 483 (PDF on fda.gov)

Observation 3

Equipment was and Materials or supplies were not disinfected prior to entering the aseptic processing areas.

Specifically,

Your pharmacy technician <Redacted B4> did not disinfect four of the I outer surfaces of the <Redacted B4> and none of the outer surfaces of the <Redacted B4> beaker of the filling solution before bringing them into the ISO 5 classified laminar airflow workstation (LAFW) on August 20 and 25, 2021. Furthermore, the technician did not sanitize his gloves while transferring the <Redacted B4> from the ISO 7 to ISO 5 classified areas within produced "AMMONIUM CHLORIDE 2% INJ" (lot 08202021@5) and "AMINOCAPROIC ACID 250 MG/ML INJ" (lot 08252021@5), respectively, purported to be sterile drug products.

Your pharmacy technician <Redacted B4> did not disinfect two of the outer surfaces of the <Redacted B4> and none of the outer surfaces of the <Redacted B4> beaker of the filling solution before bringing them into the ISO 5 classified BSC on August 18, 19, and 20, 2021. ...

Read the full 483 (PDF on fda.gov)

Observation 4

The use of sporicidal agents in the cleanrooms and ISO 5 classified aseptic processing area was inadequate.

Specifically,

A. Your pharmacy technician did not allow the required <Redacted B4> contact time (also known as "dwell time"), per your procedures and the cleaning agent manufacturer's use directions, for your disinfectant/sporicidal cleaning agent when used on the floor of the sterile suite containing the laminar airflow workstation (LAFW), durin cleaning on August 20, 2021. Most areas of the floor had a drying time of less than <Redacted B4>. Additionally I did not use the disinfectant/sporicidal cleaning agent on the ceiling and walls of the ISO 7 classified buffer room. You failed to establish an adequate contact time for your sporicidal agent used to disinfect your aseptic processing areas. listated that the disinfectant/sporicidal cleaning agent may be allowed to dry prior to <Redacted B4> though the surface may not be touched afterwards for that length of time.

disinfectant/sporicidal cleaning agent on the ceiling and walls of the ISO 7 classified buffer room. ...

Read the full 483 (PDF on fda.gov)

Observation 5

The ISO 5 classified aseptic processing areas had difficult to clean, particle-generating and visibly dirty equipment or surface.

Specifically,

A .

On August 19, 2021, during observation of the production of "TRICHLORMETHAZIDE-DEXAMETHASONE ACETATE 10 MG/0.5 MG/ML INJ" (lot 08192021@11), we observed the ceiling around the vent protruding from the top-center of the ISO 5 biological safety cabinet (BSC) had uneven surfaces with apparent caulking remnants. Additionally, there is a piece of white material that looked like caulk, approximately one centimeter in width and depth, hanging dow n from the ceiling immediately in front of the BSC access side. Your sterile pharmacy manager explained the ceiling tile had to be replaced and caulked with the replacement of the former BSC in July 2021. Also, to the right of the BSC's front-right leg, there is rust-colored staining, approximately one inch in diameter, on the tile floor.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Personnel sampling was conducted after gloves had been cleaned/disinfected. Therefore, glove fingertip sampling results are not representative of the aseptic processing environment and may not provide meaningful results.

Specifically,

On August 25, 2021, your pharmacy technician <Redacted B4> performed fingertip monitoring testing after producing "AMINOCAPROIC ACID 250 MG/ML INJ" (lot 08252021@5) immediately after finishing production; however, prior to the fingertip monitoring sampling, he directly sprayed his gloved hands with <Redacted B4>

On August 20, 2021, the same technician performed fingertip monitoring testing after producing 11AMMONIUM CHLORIDE 2% INJ" (lot 08202021@5); however, prior to the fingertip sampling, he cleaned the ISO 5 classified laminar air flow workbench (LAFW) interior ceiling, sides, and work surface with <Redacted B4>

Observation 7

Your media fills were not performed under the most challenging or stressful conditions. Therefore, there is a lack of assurance that you can aseptically produce drug products within your facility.

Specifically,

Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations. Media fills did not encompass the greatest production volume, over <Redacted B4>, before August 6, 2021. For example, aseptic lots, produced in July 2021, over <Redacted B4> quantity, include "ACETYLCYSTEINE 200 MG/ML INJ" (lots 07222021@10 and 07132021@2), "METHOCARBAMOL 100 MG/ML INJ" (lot 07092021@1), and "FOLIC ACID 10 MG/ML INJ" (lot 07082021@2).

Observation 8

1SO-5 classified areas were not certified under dynamic conditions.

Specifically,

Unidirectional airflow w as not verified under dynamic operational conditions representative of your aseptic

processing practices. Air visualization studies ("smoke studies" ) performed in your ISO 5 classified biological

safety cabinet and ISO 5 classified laminar airflow workbench in July 2021, January 2020, and June 2020 do not

demonstrate the movement of first air around equipment, supplies, or operator manipulations as observed

during sterile production operations. The smoke studies did not demonstrate unidirectional airflow, for

a[QJIQ ill

example, around equipment such as beaker, the quantity of vials filled, or the (b) (4)

housing disrupting airflow to directly over the opening of sterile vials, as observed during production of lots

08192021@11, 08192021@12, and 08202021@5.

Observation 9

Your facility failed to confirm that the quality of water was suitable for its intended use in the production of non-sterile drug products.

Specifically,

<Redacted B4> water is used in production of non-sterile drug products without raw material testing or a manufacturer's certificat e of analysis. For example <Redacted B4> and <Redacted B4> were produced with <Redacted B4> water without confirming the quality of the water.

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Pennsylvania are not checked: the Department of State’s license lookup (PALS) did not respond on November 6, 2026, and when tried again on November 7, 2026 it answered with a script-driven search application, which this index does not use; its monthly discipline reports are listed only through a script-driven search page.

Nonresident licenses and board actions in other states

These boards list a nonresident license or a board action whose record names this pharmacy’s own name, city and state.

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

LicenseType as the board gives itName on the board recordLocationStatus
NRP 1963Non Resident PharmacyBoothwyn PharmacyKennett Square, PAActive
NSC 101082Non Resident Licensed Sterile CompoundingBoothwyn Pharmacy LlcKennett Square, PADelinquent

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 7011OSPBoothwyn PharmacyKennett Square, PAActive - Restricted

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054020439LICENSED PHARMACYBOOTHWYN PHARMACY LLCKENNETT SQUARE, PAACTIVE

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002758NONRESIDENT PHARMACYBOOTHWYN PHARMACYKENNETT SQUARE, PAACTIVE (CURRENT)

Maryland Board of Pharmacy, board actions read Nov 15, 2026 (Maryland).

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0000767Non Resident PharmacyBoothwyn Pharmacy, LLCKENNETT SQUARE, PAActive

GLP-1 warning letters

FDA’s posted warning letters that name a GLP-1 drug include 1 letter to Boothwyn Pharmacy LLC. See the Boothwyn Pharmacy LLC record page for those letters and any recalls.

Later letters FDA listsLetter
Jan 16, 2026Compounding Pharmacy/Adulterated Drug ProductsSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.